Vivek Jain Sells 12,000 Shares of ICU Medical, Inc. (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $162.91, for a total value of $1,954,920.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,039,245.63. This represents a 10.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Vivek Jain also recently made the following trade(s):

• On Friday, November 1st, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00.
• On Tuesday, October 1st, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00.
• On Tuesday, September 3rd, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00.

ICU Medical Trading Down 2.7 %

NASDAQ:ICUI opened at $156.64 on Wednesday. The stock’s 50-day simple moving average is $174.32 and its 200 day simple moving average is $148.06. ICU Medical, Inc. has a 52-week low of $83.26 and a 52-week high of $196.26. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75.

Analyst Ratings Changes

ICUI has been the topic of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. Raymond James lifted their price target on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. KeyCorp upped their price objective on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Jefferies Financial Group initiated coverage on ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 target price on the stock. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $173.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC grew its stake in shares of ICU Medical by 441.7% in the second quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 4,744 shares in the last quarter. LMR Partners LLP acquired a new stake in ICU Medical in the third quarter valued at $3,884,000. Savant Capital LLC bought a new position in shares of ICU Medical in the 2nd quarter valued at about $431,000. Boston Partners acquired a new position in shares of ICU Medical during the 1st quarter worth about $790,000. Finally, Jane Street Group LLC increased its stake in shares of ICU Medical by 79.7% during the 1st quarter. Jane Street Group LLC now owns 89,852 shares of the medical instruments supplier’s stock worth $9,643,000 after purchasing an additional 39,839 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.